CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
thalidomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00019123
NCT00019123Phase 2Completed
CompareCT.gov

A PHASE II STUDY OF ORAL THALIDOMIDE FOR PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA

National Cancer Institute (NCI)·interventional·Posted Apr 13, 2004·Updated Aug 16, 2013

In Brief

A Phase 2 clinical trial evaluating thalidomide for Sarcoma. Completed, across 1 site.

Detailed Summary

RATIONALE: Thalidomide may kill cancer cells by stopping the growth of new blood vessels to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients with HIV-associated Kaposi's sarcoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 13, 2004
Enrollment StartApr 1, 1996
Study CompletionApr 1, 2004
TodayJul 2, 2026
Posted 22.2 years ago

Interventions

thalidomidedrug